Jump to content

Phentermine

From Wikipedia, the free encyclopedia

Phentermine
Clinical data
Trade namesAdipex-P, Ionamin, Suprenza, others
Other namesα,α-Dimethylphenethylamine; α,α-Dimethylphenylethylamine; α-Methylamphetamine
AHFS/Drugs.comMonograph
MedlinePlusa682187
Pregnancy
category
  • AU: B3
Dependence
liability		Physical: Not typical
Psychological: Moderate[1]
Addiction
liability		Low[2]
Routes of
administration		By mouth[3]
Drug classPsychostimulant; Appetite suppressant;[3] Norepinephrine–dopamine releasing agent
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityHigh (almost 100%)[5]
Protein binding17.5%[6]
MetabolismMinimal (6%)[6]
Elimination half-life20–25 hours, urinary pH-dependent[6][5]
ExcretionUrine (62–85% unchanged)[5][6]
Identifiers
  • 2-methyl-1-phenylpropan-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.112 Edit this at Wikidata
Chemical and physical data
FormulaC10H15N
Molar mass149.237 g·mol−1
3D model (JSmol)
  • NC(Cc1ccccc1)(C)C
  • InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3 checkY
  • Key:DHHVAGZRUROJKS-UHFFFAOYSA-N checkY
  (verify)

Phentermine, sold under the brand name Adipex-P among others, is a medication used together with diet and exercise to treat obesity.[3] It is available by itself or as the combination phentermine/topiramate.[7] Phentermine is taken by mouth.[3]

Common side effects include a fast heart beat, high blood pressure, trouble sleeping, dizziness, and restlessness.[3] Serious side effects may include abuse, but do not include pulmonary hypertension or valvular heart disease, as the latter complications were caused by the fenfluramine component of the "fen-phen" combination.[3] Phentermine is an norepinephrine and dopamine releasing agent (NDRA) and produces stimulant, rewarding, and appetite suppressant effects.[8][9][10] Chemically, it is a substituted amphetamine.[11]

Phentermine was approved for medical use in the United States in 1959.[3] It is available as a generic medication.[3] In 2022, it was the 149th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[12][13] Phentermine was withdrawn from the market in the United Kingdom in 2000, while the combination medication fen-phen, of which it was a part, was withdrawn from the market in 1997 due to side effects of fenfluramine.[14]

Medical uses

[edit]

Phentermine is used for a short period of time to promote weight loss, if exercise and calorie reduction are not sufficient, and in addition to exercise and calorie reduction.[5][15]

Phentermine is approved for up to 12 weeks of use and most weight loss occurs in the first weeks.[15] However, significant loss continues through the sixth month and has been shown to continue at a slower rate through the ninth month.[16]

Contraindications

[edit]

Use is not recommended during pregnancy or breastfeeding,[17] or with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs).[3]

Phentermine is contraindicated for users who:[5][15]

Adverse effects

[edit]

Tolerance usually occurs; however, risks of dependence and addiction are considered negligible.[16][18] People taking phentermine may be impaired when driving or operating machinery.[15] Consumption of alcohol with phentermine may produce adverse effects.[15]

There is currently no evidence regarding whether or not phentermine is safe for pregnant women.[5][15]

Other adverse effects include:[5][15]

  • Cardiovascular effects like palpitations, tachycardia, high blood pressure, precordial pain; rare cases of stroke, angina, myocardial infarction, cardiac failure and cardiac arrest have been reported.
  • Central nervous system effects like overstimulation, restlessness, nervousness, insomnia, tremor, dizziness and headache; there are rare reports of euphoria followed by fatigue and depression, and very rarely, psychotic episodes and hallucinations.
  • Gastrointestinal effects include nausea, vomiting, dry mouth, cramps, unpleasant taste, diarrhea, and constipation.
  • Other adverse effects include trouble urinating, rash, impotence, changes in libido, and facial swelling.

Interactions

[edit]

Phentermine may decrease the effect of drugs like clonidine, methyldopa, and guanethidine. Drugs to treat hypothyroidism may increase the effect of phentermine.[15]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Monoamine releasing agent

[edit]
Monoamine release of phentermine and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound NETooltip Norepinephrine DATooltip Dopamine 5-HTTooltip Serotonin Ref
Phenethylamine 10.9 39.5 >10,000 [19][20][21]
Dextroamphetamine 6.6–7.2 5.8–24.8 698–1,765 [22][23]
Dextromethamphetamine 12.3–13.8 8.5–24.5 736–1,292 [22][24]
Phentermine 28.8–39.4 262 2,575–3,511 [22][21][25]
Chlorphentermine >10,000 (RI) 935–2,650 18.2–30.9 [22][25]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assay was done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: [8][9]

Phentermine is a substrate of the monoamine transporters (MATs) and acts as a monoamine releasing agent (MRA), specifically as a norepinephrine–dopamine releasing agent (NDRA).[8][9][10] It also acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) to a lesser extent.[8][10] The drug robustly and dose-dependently elevates brain norepinephrine and dopamine levels in animals.[8] Phentermine is more potent in its effects on norepinephrine than on dopamine and the drug shows only weak effects on serotonin.[8][9][10] Unlike many other amphetamines and MRAs, phentermine is completely inactive at the vesicular monoamine transporter 2 (VMAT2).[19][26] Due to its actions on the catecholamines, phentermine produces effects including stimulation, rewarding effects, appetite suppression, and sympathomimetic effects in animals and humans.[8][6]

In terms of monoamine release in-vitro using rat brain synaptosomes, phentermine is about 6-fold less potent than dextroamphetamine in the case of norepinephrine release, 11-fold less potent than dextroamphetamine in the case of dopamine release, and has a ratio of norepinephrine release versus dopamine release of about 6.6:1 compared to dextroamphetamine's ratio of about 3.5:1.[8][9][10] It is more than 3-fold less potent than amphetamine in elevating brain dopamine and serotonin levels in rodents in vivo, is about 10-fold less potent than amphetamine in terms of self-administration in monkeys, and is a relatively weak reinforcer in rodents.[10][27] Although phentermine induces the release of dopamine at sufficiently high concentrations in vitro and at sufficiently high doses in rodents and monkeys in vivo, it may result in only weak or negligible brain dopamine release in humans at typical clinical doses.[9] This may be due to its selectivity for induction of norepinephrine over dopamine release and may be analogous to the case of ephedrine (which is at least 10-fold selective for induction of norepinephrine over dopamine release).[9] The effects of phentermine may be more related to noradrenergic activation rather than dopaminergic activity.[9] However, more research is needed to assess the preceding notions.[9]

As with other MRAs, phentermine produces dopaminergic neurotoxicity in rodents at high doses.[10] It can also produce serotonergic neurotoxicity at very high doses in rodents.[10] The clinical significance of these findings for humans, in which employed doses may be much lower, are unclear.[10]

The combination of phentermine with a serotonin releasing agent (SRA) like fenfluramine results in suppression of brain dopamine release by phentermine and marked attenuation or abolition of phentermine's stimulant and rewarding effects in animals and humans.[8][10][27][28][29][30][31] Conversely, combined phentermine and fenfluramine administration synergistically enhances the appetite suppression of these drugs in animals and results in greater weight loss than either drug alone in humans.[10] Fenfluramine produces serotonergic neurotoxicity in animals and addition of phentermine results in either no change or augmentation of this neurotoxicity.[10]

Other actions

[edit]

Phentermine has been found to be completely inactive as a ligand or agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[9][10][27] This is in contrast to the serotonin releasing agents (SRAs) fenfluramine, norfenfluramine, and to a lesser extent chlorphentermine.[9][27] However, another study found that phentermine was a weak human serotonin 5-HT2C receptor partial agonist (EC50Tooltip half-maximal effective concentration = 1,394 nM, Vmax = 66%).[27] In accordance with its lack of serotonin release and serotonin 5-HT2B receptor agonism, phentermine appears to show no risk of primary pulmonary hypertension (PPH) or valvular heart disease (VHD) in humans.[32][10][27]

Phentermine has been found to be active as an agonist of the rat and human trace amine-associated receptor 1 (TAAR1).[33][34][35][36] It appears to be a weak human TAAR1 partial agonist (EC50 = 5,470 nM and EmaxTooltip maximal efficacy = 68% in one study).[34] The drug shows reduced activity as a TAAR1 agonist compared to amphetamine.[34][36] TAAR1 agonism by amphetamines that possess this action may serve to auto-inhibit and constrain their effects.[37][38][39][40]

Phentermine is a very weak monoamine oxidase inhibitor (MAOI) in vitro.[41][10][42] It specifically inhibits monoamine oxidase A (MAO-A) (IC50Tooltip half-maximal inhibitory concentration = 85,000–143,000 nM) and monoamine oxidase B (MAO-B) (IC50 = 285,000 nM).[41][10][42] However, its potency as a MAOI is far below its potency as a monoamine releasing agent.[10] Relatedly, phentermine does not show neurochemical signs of MAOI activity in rodents in vivo.[10] As such, the significance of phentermine as an MAOI in humans is questionable.[10]

Pharmacokinetics

[edit]

Absorption

[edit]

The pharmacokinetics of phentermine are dose-dependent.[6][6] Peak concentrations of phentermine are reached 6 hours following oral administration of a dose of 15 mg.[6] The steady-state levels of phentermine with continuous administration have been found to be around 200 ng/mL in clinical studies.[6] The oral bioavailability of phentermine is not affected by intake of a high-fat meal.[6]

Distribution

[edit]

The volume of distribution of phentermine is 5 L/kg.[6] Its plasma protein binding is approximately 17.5%.[6]

Metabolism

[edit]

Phentermine undergoes minimal metabolism.[6] Only about 6% of an administered dose of phentermine is metabolized.[6] It is metabolized to a minor extent by para-hydroxylation, N-oxidation, and N-hydroxylation, followed by conjugation.[6]

Elimination

[edit]

The drug is eliminated mainly in urine.[6] It is excreted 62 to 85% unchanged in urine.[6][6] The elimination half-life of phentermine is 20 to 25 hours.[6][5] The elimination of phentermine is modified by urine acidicity or pH.[6][5] In the case of acidic urine (pH < 5), the elimination half-life of phentermine has been found to be 7 to 8 hours.[6] The clearance of phentermine is 8.79 L/h.[6]

History

[edit]

In 1959, phentermine first received approval from the US Food and Drug Administration (FDA) as an appetite suppressant.[43] Eventually a hydrochloride salt and a resin form became available.[43]

Phentermine was marketed with fenfluramine or dexfenfluramine as a combination appetite suppressant and fat burning agent under the popular name fen-phen.[44] In 1997, after 24 cases of heart valve disease in fen-phen users, fenfluramine and dexfenfluramine were voluntarily taken off the market at the request of the FDA.[45] Studies later showed nearly 30% of people taking fenfluramine or dexfenfluramine for up to 24 months had abnormal valve findings.[46]

Phentermine is still available by itself in most countries, including the US.[43] However, because it is similar to amphetamine, it is classified as a controlled substance in many countries. Internationally, phentermine is a schedule IV drug under the Convention on Psychotropic Substances.[47] In the United States, it is classified as a Schedule IV controlled substance under the Controlled Substances Act. In contrast, amphetamine preparations are classified as Schedule II controlled substances.[48]

A company called Vivus developed a combination drug, phentermine/topiramate that it originally called Qnexa and then called Qsymia, which was invented and used off-label by Thomas Najarian, who opened a weight-clinic in Los Osos, California in 2001; Najarian had previously worked at Interneuron Pharmaceuticals, which had developed one of the fen-phen drugs previously withdrawn from the market.[49] The FDA rejected the combination drug in 2010 due to concerns over its safety.[49] In 2012 the FDA approved it after Vivus re-applied with further safety data.[50] At the time, one obesity specialist estimated that around 70% of his colleagues were already prescribing the combination off-label.[49]

Chemistry

[edit]

Phentermine, also known as α,α-dimethylphenethylamine or as α-methylamphetamine, is a substituted phenethylamine and amphetamine.[51][52][53] It is the derivative of amphetamine in which a second methyl group is present at the alpha carbon.[11][51][52][53] The drug is a positional isomer of methamphetamine (N-methylamphetamine) and of other methylamphetamines such as 4-methylamphetamine.[51][52][53]

A number of derivatives of phentermine exist, including cericlamine, chlorphentermine, cloforex, clortermine, etolorex, mephentermine, 3,4-methylenedioxyphentermine (MDPH), 3,4-methylenedioxy-N-methylphentermine (MDMP or MDMPH), and pentorex, among others.[52][53] Some of these drugs, including chlorphentermine, cloforex, clortermine, and mephentermine, have been marketed as pharmaceutical drugs similarly to phentermine, for instance as appetite suppressants.[52][53]

Society and culture

[edit]

Names

[edit]

The term ‘phentermine' is contracted from phenyl-tertiary-butyl amine.

It is marketed under many brand names and formulations worldwide, including Acxion, Adipex, Adipex-P, Duromine, Elvenir, Fastin, Ionamin, Lomaira (phentermine hydrochloride), Panbesy, Qsymia (phentermine and topiramate), Razin, Redusa, Sentis, Suprenza, and Terfamex.[54]

References

[edit]
  1. ^ Tarascon Pocket Pharmacopoeia 2017 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2016. p. 7. ISBN 9781284118971.
  2. ^ Sadock BJ, Sadock VA (2010). Kaplan and Sadock's Pocket Handbook of Clinical Psychiatry. Lippincott Williams & Wilkins. p. 435. ISBN 9781605472645.
  3. ^ a b c d e f g h i "Phentermine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 13 April 2019.
  4. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  5. ^ a b c d e f g h i "METERMINE (Phentermine)" (PDF). TGA eBusiness Services. iNova Pharmaceuticals (Australia) Pty Limited. 22 July 2013. Retrieved 16 November 2013.
  6. ^ a b c d e f g h i j k l m n o p q r s t u v "Phentermine: Uses, Interactions, Mechanism of Action". DrugBank Online. 4 May 1959. Retrieved 8 January 2025.
  7. ^ "Phentermine and topiramate Uses, Side Effects & Warnings". Drugs.com. Retrieved 13 April 2019.
  8. ^ a b c d e f g h i Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
  9. ^ a b c d e f g h i j k Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
  10. ^ a b c d e f g h i j k l m n o p q r s Rothman RB, Baumann MH (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research. 51 (2): 52–65. doi:10.1002/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H. ISSN 0272-4391.
  11. ^ a b Hagel JM, Krizevski R, Marsolais F, Lewinsohn E, Facchini PJ (July 2012). "Biosynthesis of amphetamine analogs in plants". Trends in Plant Science. 17 (7): 404–412. Bibcode:2012TPS....17..404H. doi:10.1016/j.tplants.2012.03.004. PMID 22502775.
  12. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  13. ^ "Phentermine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  14. ^ Bagchi D, Preuss HG (2012). Obesity: Epidemiology, Pathophysiology, and Prevention (Second ed.). CRC Press. p. 314. ISBN 9781439854259.
  15. ^ a b c d e f g h "Phentermine label at FDA" (Last updated: January 2012). FDA. Retrieved 13 October 2016.
  16. ^ a b Glazer G (August 2001). "Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety". Archives of Internal Medicine. 161 (15): 1814–1824. doi:10.1001/archinte.161.15.1814. PMID 11493122.
  17. ^ "Phentermine Use During Pregnancy". Drugs.com. Retrieved 13 April 2019.
  18. ^ Haslam D (March 2016). "Weight management in obesity - past and present". International Journal of Clinical Practice. 70 (3): 206–217. doi:10.1111/ijcp.12771. PMC 4832440. PMID 26811245.
  19. ^ a b Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug Alcohol Depend. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
  20. ^ Forsyth AN (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024.
  21. ^ a b Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
  22. ^ a b c d Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
  23. ^ Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
  24. ^ Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–1203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
  25. ^ a b Partilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB (1999). "Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substractes". Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc (PDF). NIDA Res Monogr. Vol. 180. pp. 1–476 (252). PMID 11680410. RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM). Phentermine released all three biogenic amines with an order of potency NE (IC50 = 28.8 nM)> DA (IC50 = 262 nM)> 5-HT (IC50 = 2575 nM). [...] Chlorphentermine was a very potent 5-HT releaser (IC50 = 18.2 nM), a weaker DA releaser (IC50 = 935 nM) and inactive in the NE release assay. Chlorphentermine was a moderate potency inhibitor of [3H]NE uptake (Ki = 451 nM). [...]
  26. ^ Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (October 2006). "Interaction of amphetamines and related compounds at the vesicular monoamine transporter". J Pharmacol Exp Ther. 319 (1): 237–246. doi:10.1124/jpet.106.103622. PMID 16835371.
  27. ^ a b c d e f Rothman RB, Blough BE, Baumann MH (2008). Dopamine/serotonin releasers as medications for stimulant addictions. Progress in Brain Research. Vol. 172. pp. 385–406. doi:10.1016/S0079-6123(08)00919-9. ISBN 978-0-444-53235-0. PMID 18772043. {{cite book}}: |journal= ignored (help)
  28. ^ Rothman RB, Blough BE, Baumann MH (December 2006). "Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction". Trends Pharmacol Sci. 27 (12): 612–618. doi:10.1016/j.tips.2006.10.006. PMID 17056126.
  29. ^ Rothman RB, Baumann MH (August 2006). "Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs". Ann N Y Acad Sci. 1074 (1): 245–260. Bibcode:2006NYASA1074..245R. doi:10.1196/annals.1369.064. PMID 17105921.
  30. ^ Rothman RB, Blough BE, Baumann MH (January 2007). "Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions". AAPS J. 9 (1): E1–10. doi:10.1208/aapsj0901001. PMC 2751297. PMID 17408232.
  31. ^ Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H (April 1996). "Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers". Neuropsychopharmacology. 14 (4): 233–241. doi:10.1016/0893-133X(95)00113-R. PMID 8924191.
  32. ^ Rothman RB, Baumann MH (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates". Pharmacol Ther. 95 (1): 73–88. doi:10.1016/s0163-7258(02)00234-6. PMID 12163129.
  33. ^ Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, et al. (September 2008). "Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor". Molecular Pharmacology. 74 (3): 585–594. doi:10.1124/mol.108.048884. PMC 3766527. PMID 18524885. we confirmed agonistic activity at human TAAR1 of several other compounds, including the trace amines octopamine and tryptamine, the amphetamine derivatives l-amphetamine, d-methamphetamine, (+)-MDMA, and phentermine, and the catecholamine metabolites 3-MT and 4-MT (Bunzow et al., 2001; Lindemann and Hoener, 2005; Reese et al., 2007; Wainscott et al., 2007; Wolinsky et al., 2007; Xie and Miller, 2007; Xie et al., 2007).{{cite journal}}: CS1 maint: overridden setting (link)
  34. ^ a b c Lewin AH, Navarro HA, Mascarella SW (August 2008). "Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1". Bioorg Med Chem. 16 (15): 7415–7423. doi:10.1016/j.bmc.2008.06.009. PMC 2601700. PMID 18602830.
  35. ^ Kim N, Shin S, Bae SW (January 2021). "cAMP Biosensors Based on Genetically Encoded Fluorescent/Luminescent Proteins". Biosensors (Basel). 11 (2): 39. doi:10.3390/bios11020039. PMC 7911721. PMID 33572585.
  36. ^ a b Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol Pharmacol. 60 (6): 1181–1188. doi:10.1124/mol.60.6.1181. PMID 11723224.
  37. ^ Espinoza S, Gainetdinov RR (2014). "Neuronal Functions and Emerging Pharmacology of TAAR1". Taste and Smell. Topics in Medicinal Chemistry. Vol. 23. Cham: Springer International Publishing. pp. 175–194. doi:10.1007/7355_2014_78. ISBN 978-3-319-48925-4. Interestingly, the concentrations of amphetamine found to be necessary to activate TAAR1 are in line with what was found in drug abusers [3, 51, 52]. Thus, it is likely that some of the effects produced by amphetamines could be mediated by TAAR1. Indeed, in a study in mice, MDMA effects were found to be mediated in part by TAAR1, in a sense that MDMA auto-inhibits its neurochemical and functional actions [46]. Based on this and other studies (see other section), it has been suggested that TAAR1 could play a role in reward mechanisms and that amphetamine activity on TAAR1 counteracts their known behavioral and neurochemical effects mediated via dopamine neurotransmission.
  38. ^ Kuropka P, Zawadzki M, Szpot P (May 2023). "A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse". Hum Psychopharmacol. 38 (3): e2866. doi:10.1002/hup.2866. PMID 36866677. Another feature that distinguishes [synthetic cathinones (SCs)] from amphetamines is their negligible interaction with the trace amine associated receptor 1 (TAAR1). Activation of this receptor reduces the activity of dopaminergic neurones, thereby reducing psychostimulatory effects and addictive potential (Miller, 2011; Simmler et al., 2016). Amphetamines are potent agonists of this receptor, making them likely to self‐inhibit their stimulating effects. In contrast, SCs show negligible activity towards TAAR1 (Kolaczynska et al., 2021; Rickli et al., 2015; Simmler et al., 2014, 2016). [...] It is worth noting, however, that for TAAR1 there is considerable species variability in its interaction with ligands, and it is possible that the in vitro activity of [rodent TAAR1 agonists] may not translate into activity in the human body (Simmler et al., 2016). The lack of self‐regulation by TAAR1 may partly explain the higher addictive potential of SCs compared to amphetamines (Miller, 2011; Simmler et al., 2013).
  39. ^ Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. (January 2013). "Pharmacological characterization of designer cathinones in vitro". Br J Pharmacol. 168 (2): 458–470. doi:10.1111/j.1476-5381.2012.02145.x. PMC 3572571. PMID 22897747. β-Keto-analogue cathinones also exhibited approximately 10-fold lower affinity for the TA1 receptor compared with their respective non-β-keto amphetamines. [...] Activation of TA1 receptors negatively modulates dopaminergic neurotransmission. Importantly, methamphetamine decreased DAT surface expression via a TA1 receptor-mediated mechanism and thereby reduced the presence of its own pharmacological target (Xie and Miller, 2009). MDMA and amphetamine have been shown to produce enhanced DA and 5-HT release and locomotor activity in TA1 receptor knockout mice compared with wild-type mice (Lindemann et al., 2008; Di Cara et al., 2011). Because methamphetamine and MDMA auto-inhibit their neurochemical and functional effects via TA1 receptors, low affinity for these receptors may result in stronger effects on monoamine systems by cathinones compared with the classic amphetamines.
  40. ^ Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, et al. (November 2011). "Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA)". J Neurosci. 31 (47): 16928–16940. doi:10.1523/JNEUROSCI.2502-11.2011. PMC 6623861. PMID 22114263.
  41. ^ a b Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol. 10: 1590. doi:10.3389/fphar.2019.01590. PMC 6989591. PMID 32038257.
  42. ^ a b Ulus IH, Maher TJ, Wurtman RJ (June 2000). "Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors". Biochem Pharmacol. 59 (12): 1611–1621. doi:10.1016/s0006-2952(00)00306-3. PMID 10799660.
  43. ^ a b c Ryan DA, Bray GA (2014). "Sibutramine, Phentermine, and Diethylproprion: Sympathomimetic Drugs in the Management of Obesity". In Bray GA, Bouchard C (eds.). Handbook of Obesity - Volume 2 Clinical Applications (Fourth ed.). Hoboken: Taylor and Francis. p. 234. ISBN 9781841849829.
  44. ^ Kolata G (23 September 1997). "How Fen-Phen, A Diet 'Miracle,' Rose and Fell". New York Times. NY, NY, USA.
  45. ^ "FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)". Fda.gov. Retrieved 12 July 2013.
  46. ^ Weigle DS (June 2003). "Pharmacological therapy of obesity: past, present, and future". The Journal of Clinical Endocrinology and Metabolism. 88 (6): 2462–2469. doi:10.1210/jc.2003-030151. PMID 12788841.
  47. ^ Convention on Psychotropic Substances Archived 14 March 2014 at the Wayback Machine
  48. ^ Rueda-Clausen CF, Padwal RS, Sharma AM (August 2013). "New pharmacological approaches for obesity management". Nature Reviews. Endocrinology. 9 (8): 467–478. doi:10.1038/nrendo.2013.113. PMID 23752772. S2CID 20072687.
  49. ^ a b c Pollack A (16 February 2012). "Diet Treatment, Already in Use, to Get F.D.A. Review". The New York Times.
  50. ^ "FDA approves weight-management drug Qsymia". FDA. 17 July 2012.
  51. ^ a b c "Phentermine". PubChem. Retrieved 9 January 2025.
  52. ^ a b c d e Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 968. ISBN 978-1-4757-2085-3. Retrieved 9 January 2025.
  53. ^ a b c d e Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 824. ISBN 978-3-88763-075-1. Retrieved 9 January 2025.
  54. ^ "International brands for phentermine". Drugs.com. Retrieved 13 October 2016.
[edit]
  • "Phentermine". International Programme on Chemical Safety (IPCS). the World Health Organization (WHO).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Phentermine&oldid=1268302382"